174 related articles for article (PubMed ID: 38693590)
1. Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.
Gurgenci T; Hardy J; Huggett G; Foster K; Pelecanos A; Greer R; Philip J; Haywood A; Mendis R; Yates P; Good P
Trials; 2024 May; 25(1):293. PubMed ID: 38693590
[TBL] [Abstract][Full Text] [Related]
2. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
3. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD).
Good P; Haywood A; Gogna G; Martin J; Yates P; Greer R; Hardy J
BMC Palliat Care; 2019 Dec; 18(1):110. PubMed ID: 31810437
[TBL] [Abstract][Full Text] [Related]
4. Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).
Mersiades AJ; Tognela A; Haber PS; Stockler M; Lintzeris N; Simes J; McGregor I; Olver I; Allsop DJ; Gedye C; Kirby AC; Morton RL; Fox P; Clarke S; Briscoe K; Aghmesheh M; Wong N; Walsh A; Hahn C; Grimison P
BMJ Open; 2018 Sep; 8(9):e020745. PubMed ID: 30209152
[TBL] [Abstract][Full Text] [Related]
5. Cannabis for the treatment of ulcerative colitis.
Kafil TS; Nguyen TM; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012954. PubMed ID: 30406638
[TBL] [Abstract][Full Text] [Related]
6. Cannabis-based medicines for chronic neuropathic pain in adults.
Mücke M; Phillips T; Radbruch L; Petzke F; Häuser W
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012182. PubMed ID: 29513392
[TBL] [Abstract][Full Text] [Related]
7. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial.
Grimison P; Mersiades A; Kirby A; Lintzeris N; Morton R; Haber P; Olver I; Walsh A; McGregor I; Cheung Y; Tognela A; Hahn C; Briscoe K; Aghmesheh M; Fox P; Abdi E; Clarke S; Della-Fiorentina S; Shannon J; Gedye C; Begbie S; Simes J; Stockler M
Ann Oncol; 2020 Nov; 31(11):1553-1560. PubMed ID: 32801017
[TBL] [Abstract][Full Text] [Related]
8. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
9. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.
Bhardwaj AK; Allsop DJ; Copeland J; McGregor IS; Dunlop A; Shanahan M; Bruno R; Phung N; Montebello M; Sadler C; Gugusheff J; Jackson M; Luksza J; Lintzeris N;
BMC Psychiatry; 2018 May; 18(1):140. PubMed ID: 29776349
[TBL] [Abstract][Full Text] [Related]
10. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
11. Tetrahydrocannabinol and Cannabidiol Use in an Outpatient Palliative Medicine Population.
Highet BH; Lesser ER; Johnson PW; Kaur JS
Am J Hosp Palliat Care; 2020 Aug; 37(8):589-593. PubMed ID: 31986898
[TBL] [Abstract][Full Text] [Related]
12. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
[TBL] [Abstract][Full Text] [Related]
13. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain.
Johnson JR; Burnell-Nugent M; Lossignol D; Ganae-Motan ED; Potts R; Fallon MT
J Pain Symptom Manage; 2010 Feb; 39(2):167-79. PubMed ID: 19896326
[TBL] [Abstract][Full Text] [Related]
14. An Open-Label Pilot Study Testing the Feasibility of Assessing Total Symptom Burden in Trials of Cannabinoid Medications in Palliative Care.
Good PD; Greer RM; Huggett GE; Hardy JR
J Palliat Med; 2020 May; 23(5):650-655. PubMed ID: 31800354
[No Abstract] [Full Text] [Related]
15. Cannabidiol (CBD) and Δ
Suraev A; Grunstein RR; Marshall NS; D'Rozario AL; Gordon CJ; Bartlett DJ; Wong K; Yee BJ; Vandrey R; Irwin C; Arnold JC; McGregor IS; Hoyos CM
BMJ Open; 2020 May; 10(5):e034421. PubMed ID: 32430450
[TBL] [Abstract][Full Text] [Related]
16. Cannabis for the treatment of Crohn's disease.
Kafil TS; Nguyen TM; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012853. PubMed ID: 30407616
[TBL] [Abstract][Full Text] [Related]
17. A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.
Bhardwaj AK; Mills L; Doyle M; Sahid A; Montebello M; Monds L; Arunogiri S; Haber P; Lorenzetti V; Lubman DI; Malouf P; Harrod ME; Dunlop A; Freeman T; Lintzeris N
BMC Psychiatry; 2024 Mar; 24(1):175. PubMed ID: 38433233
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of escalating cannabinoid doses in healthy cats.
Kulpa JE; Paulionis LJ; Eglit GM; Vaughn DM
J Feline Med Surg; 2021 Dec; 23(12):1162-1175. PubMed ID: 33769105
[TBL] [Abstract][Full Text] [Related]
20. A randomised, placebo-controlled, double blind, crossover trial on the effect of a 20:1 cannabidiol: Δ9-tetrahydrocannabinol medical cannabis product on neurocognition, attention, and mood.
Manning B; Hayley AC; Catchlove S; Stough C; Downey LA
Eur Neuropsychopharmacol; 2024 May; 82():35-43. PubMed ID: 38490083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
